U.S. Markets close in 4 hrs 19 mins
  • S&P 500

    4,355.44
    -77.55 (-1.75%)
     
  • Dow 30

    34,030.68
    -554.20 (-1.60%)
     
  • Nasdaq

    14,709.86
    -334.11 (-2.22%)
     
  • Russell 2000

    2,182.39
    -54.48 (-2.44%)
     
  • Crude Oil

    70.99
    -0.98 (-1.36%)
     
  • Gold

    1,764.30
    +12.90 (+0.74%)
     
  • Silver

    22.36
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1734
    +0.0003 (+0.0235%)
     
  • 10-Yr Bond

    1.3290
    -0.0410 (-2.99%)
     
  • Vix

    24.78
    +3.97 (+19.08%)
     
  • GBP/USD

    1.3669
    -0.0069 (-0.4989%)
     
  • USD/JPY

    109.4730
    -0.4220 (-0.3840%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,095.02
    -39.36 (-3.47%)
     
  • FTSE 100

    6,908.07
    -55.57 (-0.80%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Genetron Partners With World Economic Forum; Shares Tank 9%

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Genetron Holdings Limited (GTH), one of the leading players in precision oncology in China, recently announced that it has entered into a partnership with the World Economic Forum (WEF). Under the partnership, Genetron will work for the Health and Healthcare Platform of the WEF.

Following the news release, shares of the company declined 8.6% to close at $18.55 in Friday’s trading session.

As a partner, Genetron will provide its technologies, industry expertise and insights to the WEF. The aim of the partnership is to ensure worldwide equal access to the highest standards of health and healthcare.

CEO of Genetron Sizhen Wang said, “As an international organization that is well-recognized for its efforts to promote public-private cooperation, the WEF has made a strong impact on the world’s healthcare sector. We are pleased to announce this new partnership with the WEF.” (See Genetron stock chart on TipRanks)

The stock has a Moderate Buy consensus rating based on 1 Buy. Last month, BTIG analyst Sung Ji Nam assigned a Buy rating to the stock with a price target of $25 (34.8% upside potential).

Shares of the company have gained 34.3% over the past year.

Related News:
Alpine Immune Announces Equity Offering Totaling $75M
GMS Completes Acquisition of Westside; Street Says Buy
Sun Life Closes PinnacleCare Acquisition

More recent articles from Smarter Analyst: